GUANGZHOU, China, Aug. 27 China MedicineCorporation ("CMC") (OTC Bulletin Board: CHME), a leading distributor ofprescription and over the counter pharmaceutical products, traditional Chinesemedicines, Chinese herbs, nutritional supplements, dietary supplements,medical supplies and medical formulations, today announced that managementwill present at the Roth Capital Partners New York Conference, which will beheld on September 5th and 6th at the Westin Hotel, located at Times Square inNew York, New York.
Mr. Senshan Yang, CEO of China Medicine, will present on Thursday,September 6th at 9:00 a.m. in Track 7 (The Ambassador II Room), with a break-out period immediately following. Mr. Yang will provide investors with acorporate overview, including a discussion of the Company's products, itsproduction capabilities, the evolution and drivers of the Chinesepharmaceutical market, in addition to providing a summary of recent financialresults and future growth initiatives.
Participation is by invitation only or through your Roth Capitalrepresentative. Investor meetings are available for confirmed guests, can bebooked through your representative and management will be available the entireday of Thursday, September 6 to participate. Information on the Roth New YorkConference can be found at http://www.roth.com.
About China Medicine Corporation
China Medicine is a distributor of prescription and over the counterpharmaceutical products, traditional Chinese medicines (finished medicinesmade of Chinese herbs), Chinese herbs, nutritional supplements, dietarysupplements, medical supplies and medical formulations to over 28 provincesand 800 customers within China. The Company sells more than 2,200 products andis actively building a pipeline of proprietary traditional and Chinese herbalremedy products targeting oncology, high blood pressure and the removal ofAflatoxins from food and animal feed. For more information visit the Company'swebsite at http://www.chinamedicinecorp.com.
Safe Harbor Statement
This presentation may contain forward-looking statements concerning ChinaMedicine Corp. The actual results may differ materially depending on a numberof risk factors and all forward-looking statements are expressly qualified intheir entirety by this Cautionary Statement and all risk factors detailed inthe Company's reports filed with the Securities and Exchange Commission.For more information, please contact: China Medicine Corporation Mary Xia Phone: +86-732-438-8866 Email: [email protected]
Investors: Matt Hayden, Hayden Communications Phone: +1-858-704-5065 Email: [email protected]
SOURCE China Medicine Corporation